Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11470266 | 0.98 | POLB (0.62) | POLBMEN1KMT2AKDM4EPTGS1 | |
| SCHEMBL15428758 | 0.82 | POLB (0.57) | POLBMEN1KMT2AKDM4EPTGS1 | |
| SCHEMBL4951229 | 0.79 | POLB (0.64) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL1491115 | 0.79 | POLB (0.64) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL1247688 | 0.79 | POLB (0.64) | POLBMEN1KMT2AKDM4EPTGS1 | |
| SCHEMBL1491136 | 0.78 | POLB (0.69) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL433371 | 0.78 | POLB (1.00) | POLBMEN1KMT2AKDM4EPTGS1 | |
| SCHEMBL20687950 | 0.77 | CYP17A1 (0.45) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL544667 | 0.77 | POLB (0.61) | POLBKMT2ANPC1RAB9ANR3C2 | |
| SCHEMBL27475240 | 0.76 | POLB (0.60) | POLBKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104936593-B | Oxytocin receptor agonists for the treatment of CNS disorders | 霍夫曼-拉罗奇有限公司 | 2018-05-18 | — | — | CN | disclosed |
| EP-2945624-B1 | OXYTOCIN RECEPTOR AGONISTS FOR THE TREATMENT OF CNS DISEASES | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| CN-107406451-A | Pyrrolopyrimidines and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | 福马治疗股份有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-9751870-B2 | Oxytocin receptor agonists for the treatment of CNS diseases | HOFFMAN-LA ROCHE INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| CN-105473575-A | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2016-04-06 | — | — | CN | disclosed |
| EP-2945624-A1 | OXYTOCIN RECEPTOR AGONISTS FOR THE TREATMENT OF CNS DISEASES | F. Hoffmann-La Roche AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| US-20150322058-A1 | Oxytocin receptor agonists for the treatment of CNS diseases | HOFFMANN-LA ROCHE INC. (US) | 2015-11-12 | — | — | US | disclosed |
| CN-104936593-A | Oxytocin receptor agonists for the treatment of CNS disorders | HOFFMANN LA ROCHE | 2015-09-23 | — | — | CN | disclosed |
| WO-2014111356-A1 | OXYTOCIN RECEPTOR AGONISTS FOR THE TREATMENT OF CNS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| CN-102056920-A | Tetrazole compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2011-05-11 | — | — | CN | disclosed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
| CN-101374810-A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof | SIENA BIOTECH SPA (IT) | 2009-02-25 | — | — | CN | disclosed |
| CN-101103023-A | Disubstituted ureas as kinase inhibitors | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322058-A1 | Oxytocin receptor agonists for the treatment of CNS diseases | OXTR, CRHR1, AVPR2 | POLB 3009/4885MEN1 2993/4885KMT2A 1772/4885 |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | POLB 4782/4885MEN1 683/4885KMT2A 1510/4885 |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | POLB 4087/4885MEN1 3719/4885KMT2A 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.